Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1

Robbins LLP issued a shareholder-solicitation notice reminding REPL investors of the October 5, 2026 lead plaintiff deadline in a class action alleging the company misled investors about the efficacy and viability of RP1. The underlying complaint stems from the FDA's April 10, 2026 Complete Response Letter rejecting Replimune's BLA for RP1 plus nivolumab in anti-PD-1 refractory melanoma; shares fell roughly 19% to $4.76 and then another 64% to $1.70 by April 13.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.